- Canbud (CBDX) partners with Molecular Science for R&D, testing and import of psychedelic compounds
- Molecular Science is a privately-held Toronto-based licensed dealer seeking to test controlled substances
- Canbud views Molecular’s technical skills as key to commercializing its psychedelics products in Jamaica
- Canbud Distribution Corporation is a science and technology health and wellness company
- Canbud (CBDX) is up 7.69 per cent and is currently trading at C$0.21 per share
Canbud (CBDX) partners with Molecular Science for R&D, testing and import of psychedelic compounds.
Molecular Science is a privately-held Toronto-based licensed dealer. The company is seeking approval from Health Canada for testing of controlled substances including psychedelic compounds.
Canbud believes that Molecular’s technical skills are essential to creating a niche for its psychedelic operations in Jamaica.
Additionally, Molecular’s R&D expertise will help Canbud monetize its Federal Sale for Medical Purposes License by accelerating the development of medicinal formulations for specific patients’ needs.
Canbud CEO Steve Singh commented,
“Canbud continues to grow its ecosystem with strong technical partners. Psychedelics R&D is very valuable as it potentially could move patients off synthetic drug compounds to more naturally-derived pharma compounds.”
Canbud Distribution Corporation is a science and technology health and wellness company involved in the plant-based, psychedelic pharmaceutical, non-psychedelic nutraceutical, and hemp cannabinoids verticals.
Canbud (CBDX) is up 7.69 per cent and is currently trading at C$0.21 per share as of 9:33 am EST.
